Zobrazeno 1 - 10
of 32
pro vyhledávání: '"N. Horowicz-Mehler"'
Autor:
N. Horowicz-Mehler, J.J. Doyle
Publikováno v:
Pharmaceutical Medicine. 25:361-365
While the approval of biopharmaceuticals hinges on a demonstration of safety and efficacy through randomized clinical trials, other stakeholders have historically evaluated the approved product based on repackaged clinical trial data with limited ‘
Autor:
John Doyle, Michael Hagan, Joanne Chang, Diana I. Brixner, Lee Stern, Sarah K. Hendlish, N. Horowicz-Mehler
Publikováno v:
Contraception. 78:36-41
Background The study was conducted to assess outcomes among women using the levonorgestrel-releasing intrauterine system (LNG-IUS). Study Design The data were collected via a retrospective claims database analysis of 152 women. Two nested cohorts wer
The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine
Autor:
N. Horowicz-Mehler, David R. Strutton, Roman Casciano, Lee Stern, Daniel J. Isaacman, Edward A. Kalpas, Vincent Ciuryla
Publikováno v:
Clinical Therapeutics. 30:341-357
The heptavalent pneumococcal polysaccharide-protein conjugate vaccine (PCV7) confers protection against invasive pneumococcal disease (IPD) caused by serotypes that are responsible for substantial morbidity and mortality throughout the world. In 2000
Publikováno v:
Value in Health. 18(3)
While relatively nascent, companion devices are expected to play a role along the full continuum of patient care: from prevention, diagnosis, treatment, to monitoring. Although reimbursement for companion devices is currently in early stages and cont
Publikováno v:
Value in Health. 15(4)
Publikováno v:
Value in Health. 14(3)
Publikováno v:
Value in Health. 14(3)
Publikováno v:
Value in Health. 14(3)
Publikováno v:
Value in Health. 17(3):A28-A29
Publikováno v:
Value in Health. 11(6)